Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20


Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study.

Zheng G, Xue W, Wang P, Yang F, Li B, Li X, Li Y, Yao X, Zhu F.

Sci Rep. 2016 May 27;6:26883. doi: 10.1038/srep26883.


The Historical Development of Immunoendocrine Concepts of Psychiatric Disorders and Their Therapy.

Steinberg H, Kirkby KC, Himmerich H.

Int J Mol Sci. 2015 Dec 4;16(12):28841-69. doi: 10.3390/ijms161226136. Review.


Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?

Sharma H, Santra S, Dutta A.

Future Med Chem. 2015;7(17):2385-406. doi: 10.4155/fmc.15.134. Epub 2015 Nov 30. Review.


Angelica gigas ameliorate depression-like symptoms in rats following chronic corticosterone injection.

Lee B, Sur B, Shim I, Lee H, Hahm DH.

BMC Complement Altern Med. 2015 Jul 3;15:210. doi: 10.1186/s12906-015-0746-9.


Exploiting the Polypharmacology of ß-Carbolines to Disrupt O. volvulus Molting.

Gooyit M, Tricoche N, Javor S, Lustigman S, Janda KD.

ACS Med Chem Lett. 2015 Jan 20;6(3):339-43. doi: 10.1021/ml500516r. eCollection 2015 Mar 12.


Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.

Santra S, Sharma H, Vedachalam S, Antonio T, Reith M, Dutta A.

Bioorg Med Chem. 2015 Feb 15;23(4):821-8. doi: 10.1016/j.bmc.2014.12.040. Epub 2014 Dec 25.


Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.

Dutta AK, Santra S, Sharma H, Voshavar C, Xu L, Mabrouk O, Antonio T, Reith ME.

PLoS One. 2014 Nov 26;9(11):e113420. doi: 10.1371/journal.pone.0113420. eCollection 2014.


Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.

Han M, Song C, Jeong N, Hahn HG.

ACS Med Chem Lett. 2014 Jul 10;5(9):999-1004. doi: 10.1021/ml500187a. eCollection 2014 Sep 11.


Design, Synthesis, and Optimization of Balanced Dual NK1/NK3 Receptor Antagonists.

Hanessian S, Jennequin T, Boyer N, Babonneau V, Soma U, Mannoury la Cour C, Millan MJ, De Nanteuil G.

ACS Med Chem Lett. 2014 Feb 13;5(5):550-5. doi: 10.1021/ml400528y. eCollection 2014 May 8.


The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats.

Zhang R, Li X, Shi Y, Shao Y, Sun K, Wang A, Sun F, Liu W, Wang D, Jin J, Li Y.

PLoS One. 2014 Mar 10;9(3):e91775. doi: 10.1371/journal.pone.0091775. eCollection 2014.


Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.

Sharma H, Santra S, Debnath J, Antonio T, Reith M, Dutta A.

Bioorg Med Chem. 2014 Jan 1;22(1):311-24. doi: 10.1016/j.bmc.2013.11.017. Epub 2013 Nov 19.


Molecular Neurobiology of Depression: PET Findings on the Elusive Correlation with Symptom Severity.

Smith DF, Jakobsen S.

Front Psychiatry. 2013 Mar 4;4:8. doi: 10.3389/fpsyt.2013.00008. eCollection 2013.


Multi-modality: a new approach for the treatment of major depressive disorder.

Richelson E.

Int J Neuropsychopharmacol. 2013 Jul;16(6):1433-1442. Epub 2013 Jan 30.


Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants.

Santra S, Gogoi S, Gopishetty B, Antonio T, Zhen J, Reith ME, Dutta AK.

ChemMedChem. 2012 Dec;7(12):2093-100. doi: 10.1002/cmdc.201200352. Epub 2012 Oct 11.


Therapeutic potential of metabotropic glutamate receptor modulators.

Hovelsø N, Sotty F, Montezinho LP, Pinheiro PS, Herrik KF, Mørk A.

Curr Neuropharmacol. 2012 Mar;10(1):12-48. doi: 10.2174/157015912799362805.


Benzothiazoles as probes for the 5HT1A receptor and the serotonin transporter (SERT): a search for new dual-acting agents as potential antidepressants.

Zhu XY, Etukala JR, Eyunni SV, Setola V, Roth BL, Ablordeppey SY.

Eur J Med Chem. 2012 Jul;53:124-32. doi: 10.1016/j.ejmech.2012.03.042. Epub 2012 Apr 4.


PET kinetics of radiolabeled antidepressant, [N-methyl-11C]mirtazapine, in the human brain.

Munk OL, Smith DF.

EJNMMI Res. 2011 Dec 15;1(1):36. doi: 10.1186/2191-219X-1-36.


The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents.

Dutta AK, Gopishetty B, Gogoi S, Ali S, Zhen J, Reith M.

Eur J Pharmacol. 2011 Dec 5;671(1-3):39-44. doi: 10.1016/j.ejphar.2011.09.162. Epub 2011 Sep 24.


A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation.

Fornaro M, Prestia D, Colicchio S, Perugi G.

Curr Neuropharmacol. 2010 Sep;8(3):287-304. doi: 10.2174/157015910792246227.


Getting the balance right: Established and emerging therapies for major depressive disorders.

Perović B, Jovanović M, Miljković B, Vezmar S.

Neuropsychiatr Dis Treat. 2010 Sep 7;6:343-64.

Supplemental Content

Support Center